Monte Rosa Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.60M.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $4.52M, a 32200.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $348.00K, a 2220.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $14.00K, a 94.31% decline year-over-year.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $5.72M, a 439.40% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.06M, a 47.73% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $2.03M, a 362.41% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $439.00K, a 196.62% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.60M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $4.52M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $5.72M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $348.00K 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $14.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.06M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $15.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $422.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $246.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.03M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $1.10M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $897.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $18.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $439.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $79.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $96.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $153.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $148.00K 10-K · filed 2023-03-16 | |
| 2021-06-30 | $128.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |